You are here

Article Text

Article menu

Download PDFPDF

Poster Presentations
PS01 – POSTER VIEWING SESSION – MONDAY
Monday, July 15, 2019 5:45 PM – 7:00 PM
P371 Effect of metronidazole treatment on recurrent and persistent bacterial vaginosis: a pilot study
Free
  1. Makella Coudray1,
  2. Daniel Ruiz-Perez2,
  3. Brett Colbert3,
  4. Karl Krupp4,
  5. Hansi Kumari5,
  6. Giri Narasimhan2,
  7. Kalai Mathee5,
  8. Purnima Madhivanan1
  1. 1Florida International University, Department of Epidemiology, Robert Stempel College of Public Health, Miami, USA
  2. 2Florida International University, Bioinformatics Research Group, Miami, USA
  3. 3Florida International University, Department of Biological Sciences, College of Arts and Sciences, Miami, USA
  4. 4Florida International University, Department of Health Promotion and Disease Prevention, Robert Stempel College of Public Health, Miami, USA
  5. 5Florida International University, Biomolecular Sciences Institute, Miami, USA

Abstract

Background This study aims to investigate the effect of metronidazole for the treatment of recurrent and persistent bacterial vaginosis (BV).

Methods Stored vaginal swabs of 80 African American (AA) women were randomly selected from a previously conducted clinical trial for this pilot study. Women with BV were treated with metronidazole. Vaginal smears were categorized by the Nugent score (NS) [0–3, normal; 4–6, intermediate state; 7–10, BV]. Women were classified as recurrent BV (RBV), persistent BV (PBV) or no BV based on three consecutive NS. RBV occurs when an episode of BV occurs after successful treatment of a prior episode. PBV occurs in instances when BV treatment fails to restore healthy Lactobacillus levels. All women were asymptomatic for BV at baseline and followed every two months for four months.

Results After four months, 22.5% (CI: 13%, 32%) of women did not have BV, 7.5% (CI: 2%, 13%) had RBV and 70% had PBV (CI: 60%, 80%). 30% of treated women did not have BV compared to 15% of untreated women (p=0.18). BV recurred among 12.5% of treated women and 2.5% of untreated women (p=0.2). BV persisted among 57.5% of treated women and 82.5% of untreated women (p=0.03). Women that were treated had 0.33 decreased odds (95%CI: 0.12, 0.92, p≤0.05) of having PBV as compared to untreated women. The mean age was 21.4 years (SD: 2.11 years). Prior antibiotic use among the sample was low (3.8%), and 75% of women were not treated for BV during their lifetime. Among those who were previously treated for BV, 60% were treated more than five times. Douching was reported by 49% of the sample.

Conclusion These preliminary findings suggest, standard BV treatment may not be effective among women with RBV or adherence to treatment may be low among women with asymptomatic BV.

Disclosure No significant relationships.

  • prevention
  • intervention and treatment
  • vaginal infections and dysbiosis

https://doi.org/10.1136/sextrans-2019-sti.473

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.